About Scott Mendel
Scott has deep diagnostics industry expertise, extensive financial acumen, and executive leadership experience at public companies. Scott has served as a director of Pattern Bioscience, Inc., a rapid pathogen identification and antibiotic susceptibility testing company, since May 2024 and Quantum-Si Incorporated (Nasdaq: QSI), a public protein sequencing company, since May 2023, and previously served as a director of Visby Medical, Inc., a diagnostics company. Most recently Scott served as Chairman of Akoya Biosciences, Inc., where he had been a board member since 2021.
Previously, Scott held several executive roles at GenMark Diagnostics, Inc. (“GenMark”), a syndromic molecular diagnostics company acquired by Roche in April 2021, including Chief Executive Officer (February 2020–September 2021), Chief Operating Officer (February 2019–February 2020), and Chief Financial Officer (May 2014–February 2019). Before that, he was CFO of The Active Network, Inc., a global SaaS provider, from 2010 until its acquisition by Vista Equity Partners in 2013. Earlier in his career, Scott spent over 20 years at General Electric Company holding various finance roles, including CFO of GE’s Healthcare IT division from 2003 to 2010.
Scott holds a B.S. in finance from Indiana University and an M.B.A. from Northwestern University’s Kellogg School of Management.
